Immuneel Therapeutics, co-founded by Kiran Mazumdar-Shaw, has introduced Qartemi, India's second CAR-T cell therapy, to treat B-cell Non-Ho...

India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja Hospital, led by Dr. ...

In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. ...

A key market attribute is the ability to assess the probability of a future event – and adjusting expectations accordingly. For, expectatio...

In a major policy shift, the Indian government has waived local clinical trial requirements for drugs and vaccines approved by major intern...

Indian company ImmunoACT, backed by drug maker Laurus Labs, has received approval from the Central Drugs Standard Control Organization for ...

Non-binding bid likely next week for 33.4% stake, will trigger open offer for 26% more. At current mkt value deal size could be over $6 bn ...

Laurus Labs is set to increase its stake in Immunoadoptive Cell Therapy (lmmunoACT) by 7.24% for $10.6m, taking its total stake in the comp...

The Mexican government has partnered with ImmunoAct, an IIT Bombay-incubated company which is developing cutting-edge chimeric antigen rece...

The early results from the IMAGINE study were based on the first 10 patients of the planned 24 patients to be enrolled.Both adult and child...

Amrita Hospital's Department of Hematology, Medical Oncology and BMT helps patients treat blood disorders, benign diseases, as well as bloo...

Immuneel Therapeutics is working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular im...

"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to off...

As per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subjec...

Indegene raised $200 million from investment firms Carlyle and Brighton Park Capital in February and is looking at more acquisitions in the...

The collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, said Immuneel in a press ...

It may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.